Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Lee JS"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 63
Tytuł:
Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
Autorzy:
Lee JS; Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Kim EK; Department of Pathology, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
Kim KA; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Shim HS; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 104-114. Date of Electronic Publication: 2023 Jul 24.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/surgery
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; Phosphatidylinositol 3-Kinases ; Prognosis ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; ErbB Receptors/genetics ; Genomics ; Mutation ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Autorzy:
Lee KH; Division of Medical Oncology, Department of Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee YG; Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee Y; Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Kim JH; CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Min YJ; Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
Lee GW; Division of Hemato-Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University, College of Medicine, Jinju, Korea.
Lee SS; Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
Lee KH; Division of Hematology/Oncology, Department of Internal Medicine, Yeungnam University Medical Center, Daegu, Korea.
Ko YH; Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Shim BY; Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Kim SW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Shin SW; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea.
Choi JH; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Cho EK; Division of Oncology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
Park KU; Division of Hematology/Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.
Kim JS; Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
Chun SH; Division of Medical Oncology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Wang J; Yuhan Corporation, Seoul, Korea.
Choi S; Yuhan Corporation, Seoul, Korea.
Kang JH; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2024 Jan; Vol. 56 (1), pp. 48-60. Date of Electronic Publication: 2023 Jun 27.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Morpholines*
Pyrazoles*
Pyrimidines*
Humans ; Gefitinib/therapeutic use ; Quinazolines ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Republic of Korea ; Mutation ; Protein Kinase Inhibitors/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Outcomes of surgery and subsequent therapy for central nervous system oligoprogression in EGFR-mutated NSCLC patients.
Autorzy:
Perng PS; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hsu HJ; Department of Surgery, Tainan Municipal Hospital, Tainan, Taiwan.
Lee JS; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wang LC; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Huang CY; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Tien CH; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Lai YH; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Su PL; Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Hsu HH; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chen LY; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Lee PH; Section of Neurosurgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .
Pokaż więcej
Źródło:
World journal of surgical oncology [World J Surg Oncol] 2023 Nov 25; Vol. 21 (1), pp. 368. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/therapy
Brain Neoplasms*/genetics
Brain Neoplasms*/therapy
Humans ; Female ; Retrospective Studies ; Protein Kinase Inhibitors/therapeutic use ; ErbB Receptors/genetics ; Central Nervous System
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anticancer Effects of 6-Gingerol through Downregulating Iron Transport and PD-L1 Expression in Non-Small Cell Lung Cancer Cells.
Autorzy:
Kang DY; Department of Immunology, School of Medicine, Konkuk University, Chungju 27478, Republic of Korea.
Park S; Department of Immunology, School of Medicine, Konkuk University, Chungju 27478, Republic of Korea.
Song KS; Department of Medical Science, Kosin University College of Medicine, Busan 49267, Republic of Korea.
Bae SW; Department of Chemistry and Cosmetics, Jeju National University, Jeju 63243, Republic of Korea.
Lee JS; Department of Functional Foods and Biotechnology, College of Medical Sciences, Jeonju University, Jeonju 55069, Republic of Korea.
Jang KJ; Department of Bioscience and Biotechnology, Konkuk University, Seoul 05029, Republic of Korea.
Park YM; Department of Integrative Biological Sciences and Industry, Sejong University, Seoul 05006, Republic of Korea.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Nov 15; Vol. 12 (22). Date of Electronic Publication: 2023 Nov 15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/genetics
MicroRNAs*/genetics
Humans ; B7-H1 Antigen/metabolism ; Cell Line, Tumor ; Iron
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Role of prognostic nutritional index in postoperative radiotherapy for non-small cell lung cancer.
Autorzy:
Ryu H; Department of Radiation Oncology, Seoul National University Hospital, Seoul, South Korea.
Song C; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, South Korea.
Kim JS; Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, South Korea.
Jeon JH; Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Cho S; Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Kim K; Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Jheon S; Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea.
Kim SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Kim YJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Oct; Vol. 14 (28), pp. 2859-2868. Date of Electronic Publication: 2023 Aug 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/radiotherapy
Carcinoma, Non-Small-Cell Lung*/surgery
Lung Neoplasms*/radiotherapy
Lung Neoplasms*/surgery
Lung Neoplasms*/drug therapy
Humans ; Nutrition Assessment ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Autorzy:
Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan.
Lee JS; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul, National University Bundang Hospital, Gyeonggi-do, South Korea.
Kang JH; Department of Medical Oncology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, South Korea.
Inui N; Department of Pulmonary Medicine, Hamamatsu University Hospital, Shizuoka, Japan.
Hida T; Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan.
Lee KH; Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, South Korea.
Yoshida T; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tanaka H; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Yang CT; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tamura T; Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.
Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Yu CJ; Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu County, Taipei, Taiwan.
Akamatsu H; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Takahashi S; Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 17061-17067. Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Nivolumab/adverse effects ; Bevacizumab/adverse effects ; Paclitaxel/adverse effects ; Carboplatin/adverse effects ; Platinum ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins ; Neoplasm Recurrence, Local ; Survival Analysis ; ErbB Receptors ; Receptor Protein-Tyrosine Kinases
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cryobiopsy: A Breakthrough Strategy for Clinical Utilization of Lung Cancer Organoids.
Autorzy:
Park D; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Lee D; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Kim Y; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Park Y; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 34943, Republic of Korea.
Lee YJ; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Lee JE; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Yeo MK; Department of Pathology, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Kang MW; Thoracic and Cardiovascular Surgery, School of Medicine, Chungnam National University, Munhwa-ro 282, Jung-Gu, Daejeon 35015, Republic of Korea.
Chong Y; Thoracic and Cardiovascular Surgery, School of Medicine, Chungnam National University, Munhwa-ro 282, Jung-Gu, Daejeon 35015, Republic of Korea.
Han SJ; Thoracic and Cardiovascular Surgery, School of Medicine, Chungnam National University, Munhwa-ro 282, Jung-Gu, Daejeon 35015, Republic of Korea.
Choi J; School of Life Science, Gwangju Institute of Science and Technology, Gwangju 61005, Republic of Korea.
Park JE; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
Koh Y; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
Lee J; Tomocube Inc., Daejeon 34141, Republic of Korea.
Park Y; Tomocube Inc., Daejeon 34141, Republic of Korea.; Department of Physics, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
Kim R; GENOME INSIGHT Inc., Daejeon 34051, Republic of Korea.
Lee JS; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.; GENOME INSIGHT Inc., Daejeon 34051, Republic of Korea.
Choi J; Central R&D Center, Medical & Bio Decision Co., Ltd., Suwon 16229, Republic of Korea.
Lee SH; Central R&D Center, Medical & Bio Decision Co., Ltd., Suwon 16229, Republic of Korea.
Ku B; Central R&D Center, Medical & Bio Decision Co., Ltd., Suwon 16229, Republic of Korea.
Kang DH; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Chung C; Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Pokaż więcej
Źródło:
Cells [Cells] 2023 Jul 14; Vol. 12 (14). Date of Electronic Publication: 2023 Jul 14.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cryosurgery*/methods
Lung Neoplasms*/pathology
Humans ; Bronchoscopy/methods ; Lung/pathology ; Organoids/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Estimating recurrences prevented and costs avoided with atezolizumab in early non-small cell lung cancer in the United States.
Autorzy:
Sharma R; Maple Health Group, LLC, New York, New York, USA.
Ogale S; Genentech Inc., South San Francisco, California, USA.
Smith NJ; Maple Health Group, LLC, New York, New York, USA.
Lee JS; Genentech Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Mar; Vol. 12 (6), pp. 7450-7458. Date of Electronic Publication: 2022 Nov 24.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Adult ; Humans ; United States/epidemiology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Cost-Benefit Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Autorzy:
Yang J; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Kim SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Jung EH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim SA; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Suh KJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee JY; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim JW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim JW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee JO; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim YJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee KW; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Bang SM; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.; Seoul National University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Jan; Vol. 14 (1), pp. 52-60. Date of Electronic Publication: 2022 Nov 09.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Dipeptidyl-Peptidase IV Inhibitors*/pharmacology
Dipeptidyl-Peptidase IV Inhibitors*/therapeutic use
Metformin*/pharmacology
Metformin*/therapeutic use
Antineoplastic Agents, Immunological*/therapeutic use
Humans ; Immune Checkpoint Inhibitors/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
CRBN is downregulated in lung cancer and negatively regulates TLR2, 4 and 7 stimulation in lung cancer cells.
Autorzy:
Kim MJ; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Lee JS; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Kim JY; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Choi B; Department of Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Son J; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Min Y; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Jeong SK; R&D Center, CHA Vaccine Institute, Seongnam-si, Republic of Korea.
Kim DH; Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Lee JS; Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Chun E; R&D Center, CHA Vaccine Institute, Seongnam-si, Republic of Korea.
Lee KY; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.; Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2022 Sep; Vol. 12 (9), pp. e1050.
Typ publikacji:
Letter
MeSH Terms:
Lung Neoplasms*/genetics
Toll-Like Receptor 2*/genetics
Adaptor Proteins, Signal Transducing/metabolism ; Humans ; Lung/metabolism ; Toll-Like Receptor 4 ; Toll-Like Receptor 7 ; Ubiquitin-Protein Ligases
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Stratifin (SFN) regulates lung cancer progression via nucleating the Vps34-BECN1-TRAF6 complex for autophagy induction.
Autorzy:
Kim JY; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Kim MJ; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Lee JS; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Son J; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Kim DH; Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Lee JS; Department of Precision Medicine, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Jeong SK; R&D Center, CHA Vaccine Institute, Seongnam-si, Republic of Korea.
Chun E; R&D Center, CHA Vaccine Institute, Seongnam-si, Republic of Korea.
Lee KY; Department of Immunology and Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.; Samsung Medical Center, Gangnam-gu, Republic of Korea.; Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Samsung Medical Center, Sungkyunkwan University, Gangnam-gu, Republic of Korea.; Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea.
Pokaż więcej
Źródło:
Clinical and translational medicine [Clin Transl Med] 2022 Jun; Vol. 12 (6), pp. e896.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Lung Neoplasms*/genetics
TNF Receptor-Associated Factor 6*/metabolism
Autophagy/physiology ; Beclin-1 ; Humans
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparison of the Predictive Power of a Combination versus Individual Biomarker Testing in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Autorzy:
Kim H; Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.; Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Kwon HJ; Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.; Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Kim ES; Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
Kwon S; Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.; Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Suh KJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Kim SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Kim YJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Chung JH; Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.; Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2022 Apr; Vol. 54 (2), pp. 424-433. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
B7-H1 Antigen/genetics ; B7-H1 Antigen/metabolism ; Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Mutation ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί.
Autorzy:
Lee JS; Division of Cancer Biology, Research Institute, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Korea.
Choi YE; Division of Cancer Biology, Research Institute, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Korea.
Kim S; Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Korea.
Han JY; Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Korea.
Goh SH; Division of Cancer Biology, Research Institute, National Cancer Center, 323 Ilsan-ro, Goyang 10408, Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Nov 13; Vol. 22 (22). Date of Electronic Publication: 2021 Nov 13.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
DNA-Binding Proteins*/genetics
DNA-Binding Proteins*/metabolism
Drug Delivery Systems*
Drug Resistance, Neoplasm*
Isoenzymes*/antagonists & inhibitors
Isoenzymes*/genetics
Isoenzymes*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Protein Kinase C*/antagonists & inhibitors
Protein Kinase C*/genetics
Protein Kinase C*/metabolism
Proto-Oncogene Proteins c-ets*/genetics
Proto-Oncogene Proteins c-ets*/metabolism
Transcription Factors*/genetics
Transcription Factors*/metabolism
Protein Kinase Inhibitors/*pharmacology
A549 Cells ; Amino Acid Substitution ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Gene Expression Profiling ; Gene Knockdown Techniques ; Humans ; Mutation, Missense ; Proto-Oncogene Proteins p21(ras)
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study.
Autorzy:
Kim SR; Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
Hong JH; Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
Sung SY; Department of Radiation Oncology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Kim YH; Department of Rehabilitation Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Chun SH; Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
Lee HW; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
Lee JS; Department of Rehabilitation Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Ko YH; Division of Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea. .; Cancer Research Institute, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Mar 31; Vol. 21 (1), pp. 340. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:
Journal Article
MeSH Terms:
Chemoradiotherapy/*methods
Lung Neoplasms/*drug therapy
Lung Neoplasms/*radiotherapy
Small Cell Lung Carcinoma/*drug therapy
Small Cell Lung Carcinoma/*radiotherapy
Cohort Studies ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Retrospective Studies ; Small Cell Lung Carcinoma/pathology ; Survival Analysis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Autorzy:
Jung EH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Jang HR; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Kim SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Suh KJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Kim YJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Lee JH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Chung JH; Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Kim M; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Heo DS; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2021 Mar; Vol. 12 (5), pp. 619-630. Date of Electronic Publication: 2021 Jan 17.
Typ publikacji:
Journal Article
MeSH Terms:
Antigens, CD/*metabolism
Antigens, Neoplasm/*metabolism
Biomarkers, Tumor/*metabolism
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*drug therapy
Membrane Proteins/*metabolism
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Retrospective Studies ; Lymphocyte Activation Gene 3 Protein
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical pattern of failure after a durable response to immune check inhibitors in non-small cell lung cancer patients.
Autorzy:
Heo JY; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Republic of Korea.
Yoo SH; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Suh KJ; Department of Internal Medicine, Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 beon-gil, Bundang-Gu, Seongnam, Gyeonggi-do, 13620, Republic of Korea.
Kim SH; Department of Internal Medicine, Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 beon-gil, Bundang-Gu, Seongnam, Gyeonggi-do, 13620, Republic of Korea. .
Kim YJ; Department of Internal Medicine, Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 beon-gil, Bundang-Gu, Seongnam, Gyeonggi-do, 13620, Republic of Korea.
Ock CY; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Kim M; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Heo DS; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.
Lee JS; Department of Internal Medicine, Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173 beon-gil, Bundang-Gu, Seongnam, Gyeonggi-do, 13620, Republic of Korea.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jan 28; Vol. 11 (1), pp. 2514. Date of Electronic Publication: 2021 Jan 28.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Molecular Targeted Therapy*/methods
Carcinoma, Non-Small-Cell Lung/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Lung Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/etiology ; Disease Progression ; Drug Resistance, Neoplasm ; Female ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Kaplan-Meier Estimate ; Lung Neoplasms/diagnosis ; Lung Neoplasms/etiology ; Male ; Middle Aged ; Treatment Failure ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer.
Autorzy:
Choi M; Department of Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital, Incheon, Korea.
Kim HT; Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Korea.; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Han JY; Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Korea.; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Lee GK; Department of Pathology, National Cancer Center, Goyang, Korea.
Lee SH; Department of Radiology, National Cancer Center, Goyang, Korea.
Lim KY; Department of Radiology, National Cancer Center, Goyang, Korea.
Joo J; Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, USA.
Won HJ; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Lee JS; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Lee Y; Division of Hematology and Oncology, Department of Internal Medicine, National Cancer Center, Goyang, Korea.; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2021 Jan; Vol. 53 (1), pp. 87-92. Date of Electronic Publication: 2020 Aug 13.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Squamous Cell/*drug therapy
Lung Neoplasms/*drug therapy
Pemetrexed/*therapeutic use
Salvage Therapy/*methods
Thymidylate Synthase/*therapeutic use
Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Pemetrexed/pharmacology ; Thymidylate Synthase/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.
Autorzy:
Kim M; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Ock CY; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Kim SH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Kim YJ; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Lim SM; Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, Republic of Korea.
Kim JS; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Republic of Korea.
Kim TM; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Hong SH; Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Ahn MS; Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Republic of Korea.
Shin SH; Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Republic of Korea.
Kang EJ; Department of Internal Medicine, Korea University Medical Center, Korea University College of Medicine, Seoul, Republic of Korea.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Im SW; Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.
Kim JI; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.; Genomic Medicine Institute, Medical Research Center, Seoul National University, Seoul, Republic of Korea.; Department of Biomedical Science, Seoul National University Graduate School, Seoul, Republic of Korea.
Lee JS; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Kim JH; Department of Internal Medicine, CHA Bundang Medical Center, Seongnam, Republic of Korea.
Heo DS; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2020 Dec; Vol. 11 (12), pp. 3482-3489. Date of Electronic Publication: 2020 Oct 07.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*therapeutic use
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Immunotherapy/*methods
Lung Neoplasms/*drug therapy
Adult ; Aged ; Antibodies, Monoclonal/pharmacology ; Antibodies, Monoclonal, Humanized/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea.
Autorzy:
Lim SM; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kim SW; Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kang JH; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ahn MJ; Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Kim YC; Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Lee JS; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Lee JS; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Lee SY; Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
Park KU; Department of Hematology/Oncology, Keimyung University Dongsan Hospital, Daegu, Korea.
An HJ; Division of Medical Oncology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
Cho EK; Division of Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Jang TW; Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
Kim BS; Department of Internal Medicine, Veterans Health Service Medical Center, Seoul, Korea.
Kim JH; Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.
Lee SS; Department of Hematology-Oncology, Inje University Haeundae Paik Hospital, Busan, Korea.
Na II; Division of Hematology/Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Yoo SS; Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.
Lee KH; Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2020 Oct; Vol. 52 (4), pp. 1112-1119. Date of Electronic Publication: 2020 May 15.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Agents, Immunological/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Liver Neoplasms/*drug therapy
Lung Neoplasms/*drug therapy
Nivolumab/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/adverse effects ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/secondary ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/immunology ; Female ; Humans ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Progression-Free Survival ; Protective Factors ; Republic of Korea/epidemiology ; Risk Factors ; Smoking/epidemiology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Autorzy:
Ahn MJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Han JY; Center for Lung Cancer, National Cancer Center, Goyang, Korea.
Kim DW; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Cho BC; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Kang JH; Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim SW; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Yang JC; National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan.
Mitsudomi T; Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Lee JS; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2020 Jan; Vol. 52 (1), pp. 284-291. Date of Electronic Publication: 2019 Jul 23.
Typ publikacji:
Clinical Trial, Phase II; Journal Article
MeSH Terms:
Mutation*
Acrylamides/*therapeutic use
Aniline Compounds/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*genetics
Lung Neoplasms/*drug therapy
Lung Neoplasms/*genetics
Acrylamides/administration & dosage ; Acrylamides/adverse effects ; Adult ; Aged ; Alleles ; Amino Acid Substitution ; Aniline Compounds/administration & dosage ; Aniline Compounds/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/mortality ; ErbB Receptors/genetics ; Female ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/diagnosis ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Prognosis ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Republic of Korea ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 63

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies